Can one or two high doses of oral vitamin D3 correct insufficiency in a non-supplemented rheumatologic population? by Stoll, D. et al.
ORIGINAL ARTICLE
Can one or two high doses of oral vitamin D3
correct insufficiency in a non-supplemented
rheumatologic population?
D. Stoll & J. Dudler & O. Lamy & D. Hans & M. A. Krieg &
B. Aubry-Rozier
Received: 8 September 2011 /Accepted: 16 February 2012 /Published online: 17 March 2012
# International Osteoporosis Foundation and National Osteoporosis Foundation 2012
Abstract
Summary We evaluated the effectiveness of supplementa-
tion with high dose of oral vitamin D3 to correct vitamin D
insufficiency. We have shown that one or two oral bolus of
300,000 IU of vitamin D3 can correct vitamin D insuffi-
ciency in 50% of patients and that the patients who benefit-
ed more from supplementation were those with the lowest
baseline levels.
Introduction Adherence with daily oral supplements of vi-
tamin D3 is suboptimal. We evaluated the effectiveness of a
single high dose of oral vitamin D3 (300,000 IU) to correct
vitamin D insufficiency in a rheumatologic population.
Methods Over 1 month, 292 patients had levels of 25-
OH vitamin D determined. Results were classified as:
deficiency <10 ng/ml, insufficiency ≥10 to 30 ng/ml,
and normal ≥30 ng/ml. We added a category using the
IOM recommended cut-off of 20 ng/ml. Patients with
deficient or normal levels were excluded, as well as
patients already supplemented with vitamin D3. Selected
patients (141) with vitamin D insufficiency (18.5 ng/ml (10.2–
29.1) received a prescription for 300,000 IU of oral vitamin
D3 and were asked to return after 3 (M3) and 6 months (M6).
Patients still insufficient at M3 received a second prescription
for 300,000 IU of oral vitamin D3. Relation between changes
in 25-OH vitamin D between M3 and M0 and baseline values
were assessed.
Results Patients (124) had a blood test at M3. Two (2%) had
deficiency (8.1 ng/ml (7.5–8.7)) and 50 (40%) normal results
(36.7 ng/ml (30.5–5.5)). Seventy-two (58%) were insufficient
(23.6 ng/ml (13.8–29.8)) and received a second prescription
for 300,000 IU of oral vitamin D3. Of the 50/124 patients who
had normal results at M3 and did not receive a second pre-
scription, 36 (72%) had a test at M6. Seventeen (47%) had
normal results (34.8 ng/ml (30.3–42.8)) and 19 (53%) were
insufficient (25.6 ng/ml (15.2–29.9)). Of the 72/124 patients
who receive a second prescription, 54 (75%) had a test at M6.
Twenty-eight (52%) had insufficiency (23.2 ng/ml (12.8–
28.7)) and 26 (48%) had normal results (33.8 ng/ml (30.0–
43.7)). At M3, 84% patients achieved a 25-OH vitamin D
level >20 ng/ml. The lowest the baseline value, the highest the
change after 3 months (negative relation with a correlation
coefficient r0−0.3, p00.0007).
Conclusions We have shown that one or two oral bolus of
300,000 IU of vitamin D3 can correct vitamin D insuffi-
ciency in 50% of patients.
Keywords Single high dose of vitamin D . Vitamin D
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Introduction
Vitamin D insufficiency is highly prevalent [1]. There is a
large amount of evidence that with a daily oral intake of 700 to
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1,000 IU of vitamin D3, the often-recommended serum level
of 20–30 ng/ml of 25-OH vitamin D is usually achieved and
up to 20% of falls and fractures are prevented [2–6]. In
epidemiological studies, this recommended level has been
associated with decreased cardiovascular, oncologic, and
rheumatologic diseases [7, 8]. However, several recent works
also question these findings and suggest that we have been
overestimating vitamin D insufficiency using high cut-offs
(such as 30 ng/ml) and its consequences[9–11].
Adherence with daily oral supplements of vitamin D3 is
suboptimal, with 50–75% of the population on oral daily
vitamin D supplementation still exhibiting vitamin D insuf-
ficiency depending of the dose administered [12, 13]. If
vitamin D supplementation is taken less than 80% of the
time, the benefits against fractures and falls are lost [12].
We elected to evaluate the effectiveness of supplementation
with a single high dose of oral vitamin D3 (300,000 UI) to
correct vitamin D insufficiency, a simple procedure that has
gained wide acceptance in Switzerland despite controversy
and the lack of any formal demonstration of effectiveness.
Methods
Study design and subjects
Over 1 month (November 2009), 292 consecutive patients
attending our Rheumatology Outpatient Clinic at the Uni-
versity Hospital of Lausanne (latitude 46.52°N) had their
blood level of 25-OH vitamin D measured. 25-OH vitamin
D levels were determined using radioimmunologic assay
with extraction (25-hydroxyvitamin D 125I RIA Kit, Dia-
Sorin®): the first step involves rapid extraction of 25-OH
vitamin D and other hydroxylated metabolites from serum
with acetonitrile. Following extraction, the treated sample is
then assayed using equilibrium RIA procedure based on an
antibody with specificity to 25-OH vitamin D.
Patients were classified into one of the following catego-
ries according to their 25-OH vitamin D level: deficient with
levels <10 ng/ml (<25 nmol/l), insufficient with levels ≥10
to <30 ng/ml (≥25 to 75 nmol/l), and normal with
levels ≥30 ng/ml (≥75 nmol/l). These definitions were based
on a widely recognized definition of insufficiency and defi-
ciency [8]. They are not exactly the same as those used in the
recent Endocrine Society and Institute of Medicine (IOM)
recommendations [14, 15]. We then a posteriori added a cate-
gory using the IOM recommended cut-off of 20 ng/ml [14].
For the present study, only patients with vitamin D in-
sufficiency (≥10 ng/ml to <30 μg/l) were considered.
Patients with deficient or normal levels were excluded, as
well as patients already supplemented with daily oral vita-
min D3 or who had received a single high dose of oral or
intramuscular vitamin D3 within the previous 6 months.
At baseline, all selected patients received a prescription for
a single high dose of 300,000 IU of oral vitamin D3 (Vitamin
D3 Streuli® 1 ml, Streuli Pharma SA, 8730 Uznach, Switzer-
land) for the non-supervised administration of vitamin D3. No
guidance was given on how to take the vitamin D. They then
were asked to return after 3 (M3) and 6months (M6) for a new
determination of their 25-OH vitamin D levels. Patients still
insufficient (≥10 ng/ml to <30 μg/l) at M3 received a second
prescription for another single high dose of 300,000 IU of oral
vitamin D3 (Vitamin D3 Streuli® 1 ml). Patients with defi-
ciency at M3 were excluded from further follow-up, as they
were administered either higher or intramuscular supplemen-
tation of vitamin D3.
This study is aligned with the Lausanne University Hos-
pital Ethics committee. No outside funds were necessary.
All patients were orally informed and oral consent was
mandatory but no written informed consent was signed.
Statistical analysis
Relation between changes in 25-OH vitamin D between M3
and M0 and baseline values and relation between changes
between M6 and M3 and M3 values were assessed by linear
regression with statistical significance for p value<0.05. All
analyses were performed using Stata 12.0 statistical soft-
ware (Stata Corp, College station, TX, USA).
Results
Two hundred ninety-two patients had their level of 25-OH
vitamin D determined in November 2009 [13]. The details
of the 25-OH vitamin D results of the total sample of the 292
patients have been published recently [13]. Briefly, 7% were
deficient, 79% insufficient, and 14% had normal results. We
excluded 124 patients for the present analysis, 20 patients
who had previously received a single dose of 300,000 IU of
vitamin D3 within the preceding 6 months and 104 patients
who were currently taking daily oral vitamin D3 supple-
ments. Of the remaining 168 patients, 16 patients had levels
of <10 ng/ml and 11 patients had levels of ≥30 ng/ml. One
hundred forty-one remaining patients (84%) presented with
vitamin D insufficiency (84 patients with levels of ≥10
to <20 ng/ml and 57 patients with levels of ≥20 to <30
ng/ml). Patients' characteristics are in the Table 1.
All patients were given a prescription for a single high dose
of 300,000 IU of oral vitamin D3. Figures 1 and 2 give the
flow of the patients and the main findings at months 3 and 6.
Vitamin D levels at month 3 (M3)
One hundred and twenty-four patients (88%) returned to our
Rheumatology Clinic at 3 months to have their 25-OH
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vitamin D serum levels re-measured. Their demographic
characteristics (mean age 49 years old [range 17–84], 65%
women) did not differ from the original subject sample.
Their mean serum level of 25-OH vitamin D had in-
creased to 28.6 ng/ml (range 7.5–56.5), and 50/124 (40%)
now had levels falling within the normal range (mean 25-
OH vitamin D 36.7 ng/ml [range 30.5–56.5]). Nevertheless,
despite high dose supplementation, 58% (72/124) still suf-
fered from vitamin D insufficiency (mean 25-OH vitamin D
23.6 ng/ml [range 13.8–29.8]) and 2 (2%) even had evolved
to frank deficiency (25-OH vitamin D levels of 7.5 and
8.7 ng/ml, respectively). All insufficient patients received a
second prescription for another single high dose of
300,000 IU of oral vitamin D3. The two patients with
deficiency at 3 months were excluded from further analysis.
Vitamin D levels at month 6 (M6)
Of the 122 remaining patients who were either vitamin D
normal or insufficient at 3 months, 90 were available at
6 months for a final evaluation: 54 of the 72 (75%) patients
are still insufficient at M3, and 36 of the 50 (72%) patients
have normal levels at M3.
Among the 54 initially (M0 and M3) insufficient patients,
26 (48%) now had normal levels of 25-OH vitamin D (mean
33.8 ng/ml, range 30.0–43.7), while 28 (52%) remained
insufficient (mean 25-OH vitamin D serum level 23.2 ng/ml
[range 12.8–28.7]). None were deficient.
Of the 36 patients who had normalized their serum vita-
min D levels by 3 months after a single high dose of
300,000 IU of vitamin D3 and did not receive a second
prescription, 47% (17/36) still had normal levels at 6 months
(mean 25-OH vitamin D serum level 34.8 ng/ml [range
30.3–42.8]), while 53% (19/36) were again within the in-
sufficiency range (mean 25-OH vitamin D serum level
25.6 ng/ml [range 15.2–29.9]). None were deficient.
At M3, 84% (104/124) patients achieved a 25-OH vita-
min D level >20 ng/ml. Of those who received only one
high dose of vitamin D3 at baseline, 94% (34/36) had a 25-
OH vitamin D level >20 ng/ml at M6. Of those who re-
ceived two high doses of vitamin D3, a single dose both at
baseline and M3, 91% (49/54) exhibited a 25-OH vitamin D
level of >20 ng/ml at M6.
Differences between M3 and M0 compared to baseline
values of 25-OH Vitamin D were available for 124 patients.
There was a significant negative relation with a correlation
coefficient r0−0.3, p00.0007: the lowest the baseline value,
the highest the change after 3 months. Identical analysis was
performed for differences between M6 and M3 25-OH vita-
min D levels for 54 patients who received a second dose at
3 months. There was no more correlation between the differ-
ences and values 3 months before (r0−0.11, p00.43) (Fig. 3).
Discussion
We previously have demonstrated that hypovitaminosis D
was highly prevalent in a population of Swiss rheumatology
outpatients in autumn, and that classic oral daily supplemen-
tation with vitamin D3 was inefficient, with 75% of the
patients on oral supplementation either deficient or insuffi-
cient in vitamin D, probably secondary to poor adherence
Table 1 Characteristics of the 141 insufficient patients at baseline
Mean ± SD Range
Age (years) 49.2±13.1 17–84
BMI (kg/m²) 26.4±5.5 17–42
Percentage
Inflammatory disease 84%
Degenerative disease 16%
Osteoporosis 5%
Fig. 1 Effect of 1–2 high dose
(s) of vitamin D3 on patients
with insufficiency
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[13]. Another Swiss study demonstrated that less than 5% of
the elderly who recently had suffered from a hip fracture had
vitamin D levels higher than the recommended 30 ng/ml,
and that about 70% of the European population is below this
threshold [1].
As normalization of vitamin D levels appears to have
clear benefits in the general population, we decided to
evaluate the true effectiveness of supplementation with a
single oral high dose of vitamin D3 (300,000 IU) to correct
vitamin D insufficiency. This is a simple procedure that has
gained wide-spread acceptance in Switzerland, despite the
lack of any formal demonstration of its effectiveness. We
began this study in 2009, before there was any significant
controversy about the benefits of single high doses of vita-
min D3 without calcium supplementation on fracture occur-
rence [16–18].
Even if approximately 50% of our patients achieved
normal results at 3 months after a single high dose of
vitamin D3, this still means that this level of supplementa-
tion was inadequate to correct insufficiency in the other half,
even if the mean serum levels at month 3 were not much
lower than the often recommended cut-off of 30 ng/ml. On
the other hand, the 20 ng/ml cut-off recently recommended
by the IOM was achieved by more than 80% and more than
90% of patients at months 3 and 6, respectively.
Pharmacokinetic studies show that 25-OH vitamin D
levels peak at 7 to 21 days and, thereafter, decrease slowly
[19, 20]. It is known that any incremental increase in 25-OH
vitamin D is likely to be lower in those already replete prior
to supplementation [21]. The results at 3 months are, inter-
estingly, not very different from the levels attained on
800 IU of oral daily vitamin D3 in some studies, when
patients are adherent to the prescription [22]. The patients
who seemed to benefit more from supplementation were
those with the lowest baseline levels. However, we were
unable to predict normalization of vitamin D from baseline
values.
We also were unable to predict the evolution of vitamin D
levels after supplementation. About half of patients whose
vitamin D levels had normalized by 3 months continued to
exhibit normal levels at 6 months; meanwhile, by 6 months,
a second prescription of 300,000 IU of oral vitamin D3,
administered at M3, had normalized half of those insuffi-
cient at 3 months. These results are in congruence with the
results of a recent study involving a smaller and older
population of patients with vitamin D deficiency, where
important individual variations were observed, despite the
administration of a single high dose of 300,000 IU of
vitamin D3 under supervision [23].
Our study had four main limitations. First, it is impossi-
ble to know for sure whether our patients really took their
supplementation as prescribed and how they took it, as the
administration was not supervised and adherence was not
evaluated. Second, we lost 36% of our subjects over the
course of follow-up (12% by 3 months). Third, the rele-
vance of our results and the conclusion we can draw from
them are also limited by the fact that we didn't measure other
parameters such as calcium (could be suggested for safety
reason) or parathyroid hormone (could help to determine the
individual optimal 25-OH vitamin D level). Fourth, we
didn't evaluate vitamin D level before 3 months, and if we
cannot exclude correction of the insufficiency before that
time point as it has been strongly supported by the literature
[17, 21], the benefits would be nevertheless transient in this
subgroup. Finally, it has been suggested that plasma con-
centrations of 25-OH vitamin D may be decreased by in-
flammation and therefore less reliable in patient with
systemic inflammatory disease. We could not address this
problem with our study design. However, it appears unlikely
that inflammation would be a major parameter in a treated
population with mostly mild or absent inflammation [24].
On the other hand, this renders ours as a “real life”
practical study that clearly demonstrates that a single high
dose of vitamin D3 is insufficient to completely correct and
avoid vitamin D insufficiency in this setting, if 30 ng/ml is
Fig. 2 Effect of high dose(s) of vitamin D3 on patients with insuffi-
ciency at 3 and 6 months
Fig. 3 Change in 25-OH vitamin D 3 months after the first dose
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the goal. In contrast, one or two oral boluses of 300,000 IU
of vitamin D3 in autumn and winter was a good means of
preventing the 25-OH vitamin D nadir that usually is
observed in the spring, since the average level was definitely
higher than 20 ng/ml. It also is possible that levels higher
than 20 ng/ml (and lower than 30 ng/ml) are adequate in a
rheumatologic population (with or without osteoporosis), as
recent reviews of evidence suggest [8]. Indeed, evidence for
optimal bone health relates to level between 20 and 25 ng/ml,
higher levels mainly relate to muscle function.
Finally, as suggested in recent publications, daily vitamin
D3 supplements, with or without co-administered calcium,
are probably more physiological than single high doses of
oral vitamin D3. Nevertheless, adherence often is low and
the efficiency of such an approach appears limited, as we
have observed in our population. There have been doubts
that very high doses of vitamin D3 might be harmful. Indeed
100,000 IU seems to be effective in reducing the occurrence
of falls and fractures but 300,000 to 500,000 IU have been
shown to actually increase this risk [5, 17, 25]. Other studies
suggest that single oral doses of 300,000 IU of vitamin D3
are safe and more effective than 800 IU per day to increase
serum 25-0H vitamin D [26, 27]. Others suggest that vita-
min D3 is more potent than vitamin D2 [28]. This area of
controversy needs further evaluation and was not the pur-
pose of our study. A single high dose of vitamin D3 is
certainly appealing. However, the safety of such an
approach still must be determined [17], as must its modal-
ities of application, to ensure correction of the insufficiency
in as large a percentage of patients as possible.
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